Study to Evaluate the Effect of Dexmedetomidine in Attenuating the Hemodynamic and Neuroendocrinal Responses to Skull-Pin Head-Holder Application during Craniotomy by Renganathan, T
STUDY TO EVALUATE THE EFFECT OF 
DEXMEDETOMIDINE IN ATTENUATING THE 
HEMODYNAMIC AND NEUROENDOCRINAL 
RESPONSES TO SKULL-PIN HEAD-HOLDER 
APPLICATION DURING CRANIOTOMY
Dissertation submitted to
THE TAMILNADU Dr. M.G.R. MEDICAL UNIVERSITY
In partial fulfillment for the award of the degree of
DOCTOR OF MEDICINE
IN
ANAESTHESIOLOGY
BRANCH - X
APRIL 2012
INSTITUTE OF ANAESTHESIOLOGY & CRITICAL CARE
MADRAS MEDICAL COLLEGE
CHENNAI – 600 003.
CERTIFICATE
This is to certify that the dissertation entitled, “STUDY TO 
EVALUATE THE EFFECT OF DEXMEDETOMIDINE IN 
ATTENUATING THE HEMODYNAMIC AND NEUROENDOCRINAL 
RESPONSES TO SKULL-PIN HEAD-HOLDER APPLICATION 
DURING CRANIOTOMY” submitted by  Dr. T. RENGANATHAN in 
partial fulfillment for the award of the degree of Doctor of Medicine in 
Anaesthesiology by the Tamil Nadu Dr. M.G.R. Medical University, Chennai is 
a bonafide record of the work done by him in the INSTITUTE OF 
ANAESTHESIOLOGY & CRITICAL CARE, Madras Medical College, during 
the academic year 2009-2012.
PROF. Dr. C.R. KANYAKUMARI, M.D.,D.A.
DIRECTOR AND PROFESSOR,
INSTITUTE OF ANAESTHESIOLOGY
& CRITICAL CARE,
MADRAS MEDICAL COLLEGE,
CHENNAI – 600 003.
Dr. V. KANAGASABAI, M.D.,
DEAN
MADRAS MEDICAL COLLEGE,
CHENNAI – 600 003.
                                                       
DECLARATION
I hereby declare  that  the  dissertation  entitled “STUDY TO 
EVALUATE THE EFFECT OF DEXMEDETOMIDINE IN 
ATTENUATING THE HEMODYNAMIC AND 
NEUROENDOCRINAL RESPONSES TO SKULL-PIN HEAD-
HOLDER APPLICATION DURING CRANIOTOMY” has been 
prepared by me under the Guidance of  PROF. DR 
C.R.KANYAKUMARI M.D.,D.A.,  Professor and Director,Institute Of 
Anesthesiology And Critical Care, Madras  Medical  College, Chennai in 
partial fulfillment of the regulations for the award of  the degree  of M.D
[Anaesthesiology], examination to be held inApril 2012. This study was 
conducted at Madras Medical College and Rajiv Gandhi Government 
General Hospital, Chennai.I have not submitted this dissertation previously 
to any university for the award of any degree or diploma.
Place: Chennai                                                  Dr. T. RENGANATHAN 
Date :
ACKNOWLEDGEMENT
I am extremely thankful to Dr. KANAGASABAI, M.D., Dean, 
Madras Medical College & Rajiv Gandhi Govt. General Hospital, for his 
permission to carry out this study.
I am immensely grateful to PROF. Dr. C.R. KANYAKUMARI 
M.D., D.A., Director and Professor, Institute of Anaesthesiology and 
Critical Care, for her concern and support in conducting this study.
I am thankful to Professors, T.VENKATACHALAM, M.D.,D.A., 
Dr. ESTHER SUDHARSHINIRAJKUMAR, MD.,DA.,
Dr. D. GANDHIMATHI, MD., DA., Dr. B. KALA, MD., DA., and 
Dr. SAMUEL PRABAKARAN, MD., DA, Institute of Anaeshesiology 
and Critical Care, for their constant motivation and valuable suggestions.
I am thankful to Dr. RADHAKRISHNAN M.D., D.A. and all my 
Assistant Professors for their guidance and help.
I am thankful to the Institutional Ethical Committee for their 
guidance and approval for this study.
Last but not the least; I thank all the patients for willingly submitting 
themselves for this study. 
CONTENTS
S.No. TOPIC Page No.
1. INTRODUCTION 1
2. AIM OF THE STUDY 4
3. NOXIOUS STIMULUS – ITS RESPONSES 5
4.
METHODS TO ATTENUATE HEMODYNAMIC 
AND STRESS RESPONSES
11
5.
PHARMOCOLOGY OF THE STUDY DRUG
DEXMEDETOMIDINE
16
6. REVIEW OF LITERATURE 26
7. MATERIALS AND METHOD 34
8. OBSERVATION AND ANALYSIS 39
9. DISCUSSION 45
10. SUMMARY 51
11. CONCLUSION 53
BIBLIOGRAPHY
ETHICAL COMMITTEE APPROVAL FORM
PROFORMA
MASTER CHART
1INTRODUCTION
The Mayfield skull-pin head holder is used to stabilize the head 
during neuro surgical procedures. 
They support the head without any direct pressure on the face, allow 
access to the airway and hold the head firmly in one position that can be 
finely adjusted for optimal neurosurgical exposure.
Although it is an instrument of barbaric appearance, it is essential 
for operations in the sitting position and highly desirable for cervical or 
intracranial procedures in the prone or lateral position.
Different anesthetic and pharmacologic technique, including local 
anesthetic, narcotics, antihypertensive, and deepening of anesthesia with 
inhalation anesthetics, have been used to blunt this deleterious effect with 
variable success.
When properly applied, the pins cause considerable periosteal
stimulation. This results in abrupt increase in BP and CBF under GA1,2 . 
These hemodynamic responses may lead to brain edema, increase in 
ICP or ICH in aneurysm patients. Different anesthetic techniques have 
been used to blunt this deleterious effect with variable success.4-7
2The stress response to intense nociceptive surgical stimulus   is 
characterized by increased secretion of pituitary hormones and activation 
of the sympathetic nervous system. 
Attenuation of the cardiovascular and neuroendocrine responses to 
intense noxious stimuli during operation may improve outcome by 
beneficial effects on organ function.
Dexmedetomidine is a highly specific potent and selective α-2 
adrenoreceptor agonist. It has sedative, analgesic, and anesthetic – sparing 
effects and it decreases HR, MAP and sympathetic nervous system activity 
in a dose dependent fashion11,12. Also it has the potential to exert inhibitory 
effects on cortisol and catecholamine synthesis13,14.
In this prospective randomized controlled study the hypotheses that 
dexmedetomidine would attenuate the increase in HR,MAP,  plasma 
glucose, cortisol and prolactin concentrations to skull pin placement for 
craniotomies was investigated .
3MAY FIELD HEAD REST
4AIM OF THE STUDY
     This study was done with the following intention :  “To evaluate the 
effect of dexmedetomidine in attenuating the hemodynamic and 
neuroendocrinal responses to skull pin head holder application during 
craniotomy”
                         
5NOXIOUS STIMULUS – ITS RESPONSES
Prys-Roberts defined noxious stimulation as a mechanical, chemical, 
thermal, or radiation induced trespass causing potential or actual cell 
damage (fig. 1) shows the somatic and autonomic responses to noxious 
stimulation.
Noxious stimulation arises from somatic or visceral tissue and 
responses can be somatic or autonomic.
Somatic responses include both sensory and motor activity 
Sensory response is perception of pain 
A motor response is withdrawal of the stimulated part. This is the 
same concept that Eger and colleagues used more than four decades earlier
when they defined the MAC as the drug concentration that blocked 
movement in response to noxious stimulation.
Prys – Roberts divided autonomic responses into four categories: 
breathing, haemodynamic, sudomotor and hormonal
6HEMODYNAMIC RESPONSES
The hemodynamic response consists of autonomic responses to 
noxious stimuli, namely- increased sympathetic tone, which elevates blood 
pressure and the heart rate.
The sudomotor response consist of sweating, whereas the hormonal 
responses consist of catecholamine’s and corticosteroids 
Prys-Roberts considered pain relief, muscle relaxation and 
suppression of autonomic activity to be discrete pharmacologic effects. 
Some drugs can produce all these end points. Others produce only one or 
two. 
STRESS RESPONSES
The stress responses was initially described by Hans selye as “the 
non- specific response of the body to any demand upon it”
The human body is an adaptable organism that has many interrelated 
mechanisms designed to identify, respond and neutralize both internal and 
external events that threatens or upsets homeostasis. 
Anaesthesia and surgery involve manipulation of body physiology 
leading to activation of the body’s responses to stress. 
7The stress response evolved as a mechanism for assisting the
organism in reacting to immediate danger 
Although once regarded positively as the body’s defense
mechanism. Today the stress response is regarded more equivocally since 
its physiologic consequences, especially increasing the output of various 
organ systems, may lead to increased morbidity and mortality by 
overtaxing already compromised organ system.
THE HYPOTHALAMIC PITUITARY AXIS:
The response to surgical and traumatic stress is triggered by 
hypothalamic activation secondary to afferent neuronal input from an area 
of injury such as inflammatory cytokines, TNF –α, IL-1 and IL6
Hypothalamic activation increases the activity of the sympathetic 
nervous system, which increases the output of the cardiovascular system,
stimulates the adrenal medulla to secrete epinephrine and the pancreas to 
secrete glucagon 
The endocrine system 
     The hypothalamic pituitary axis is the main controller of the endocrine 
system which in turn controls much of the body’s metabolic functioning. 
8The endocrine hormones are major mediators of the metabolic response to 
stress. The hormones glucagon, cortisol and catecholamine oppose the 
effects of insulin on glucose and lipid metabolism and are thus called the 
counter regulatory hormones.
SYMPATHO ADRENERGIC SYSTEM
The sympathoadrenergic system composed of the sympathetic 
nervous system and adrenal gland, produces and secretes the 
catecholamines: norepinephrine epinephrine and dopamine.
Catecholamines have major effect on the cardiovascular system and 
also have major metabolic effect.
Glucagon- Insulin
Glucagon and insulin are both secreted by the pancreas, the former 
by the alpha cell, the later by the beta cells. The principal action of 
glucagon is to stimulate hepatic glycogenolysis and gluconeogenesis. 
Serum glucagon concentration rises after most types of major 
surgery. The glucagon - insulin ratio increase because, insulin 
concentration decrease during surgery.
9Glucocorticoid 
Cortisol is a major stress hormone whose plasma levels are 
markedly elevated after surgical and traumatic stress. This is mainly due to 
enhanced secretion by the adrenal cortex.
In addition, this cortisol production is minimally suppressed by 
exogenous glucocorticoid administration. This was demonstrated by the 
inability of 24 mg/day of dexamethasone administered for 2days after 
craniotomy to suppress the elevated concentration of either ACTH or 
cortisol.
Cortisol is thought to cause insulin resistance by decreasing the rate 
of insulin activation of the glucose uptake system.
Cortisol is a vital mediator of stress because it facilitates 
catecholamine action and secretion, thus helping to maintain 
cardiovascular stability during surgical stress.
The counter regulatory hormones
The hormones, glucagon, catecholamine, and cortisol are called 
counter regulator hormones because they oppose the effect of insulin and 
act synergistically to increase glucose production.
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PROLACTIN
Prolactin release from the pituitary gland is a very sensitive marker 
of both physical and physiological stress in mammals.
The prolactin surge results from a general increase in the adrenergic 
activity in the hypothalamus. The stress induced prolactin release is a 
rapid, strong and transient response that can be evoked by large number of 
medical and surgical procedures26-28. 
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METHODS TO ATTENUATE HEMODYNAMIC AND 
STRESS RESPONSES
Control of hemodynamic parameters during neurosurgical procedure 
is of great concern to the neuro-anaesthesiologist whose goals include 
optimal cerebral perfusion pressure.
Also, the balance of myocardial oxygen supply and demand must be 
preserved to minimize the risk of per-operative myocardial ischemia and 
infarction.
Factors affecting myocardial oxygen supply and demand  
Supply 
1. Heart rate –diastolic time depends upon heart rate. Hence slower the 
heart rate, more the diastolic time and more the oxygen supply to the 
myocardium.
2. Coronary perfusion pressure – depends on aortic diastolic pressure 
and left ventricular end-diastolic pressure. It increases with a high 
aortic diastolic pressure and a low end diastolic pressure.
3. Arterial oxygen content – depends upon arterial oxygen tension and 
hemoglobin concentration.
4. Coronary vessel diameter.
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Demand: 
1. Basal requirement 
2. Heart rate
3. Wall tension – preload, afterload
4. Contractility
     A number of methods were used to attenuate cardiovascular 
response due to laryngoscopy and endotracheal intubation and skull pin 
placement 
1. Deepening of general anesthesia
     Inhalational agents – the deep level of anesthesia achieved by 
inhalational agents resulted in profound cardiovascular depression prior to 
skull pin placement 
2. Lignocaine 
Lignocaine has been demonstrated to produce intense analgesia 
when injected IV . Yukioka, et al demonstrated that the cough reflex was 
suppressed during intubation of trachea when plasma concentration of 
lignocaine was more than 2mcg/ml.
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Levin R, et al demonstrated local mepivacaine infiltration safely 
protected against potentially dangerous increase in arterial pressure when 
the May field head holder was used  
Mechanism 
1. By increasing the depth of anesthesia 
2. Potentiation of effect of N2O anesthesia and reduction of 
MAC of volatile  agents
3. Direct cardiac depression 
4. Peripheral vasodilatation
5. Anti-arrythmic properties
3. Clonidine 
It is an alpha 2 receptor agonist. Clonidine 4 to 5 mcg/kg orally 60 
to 120 minutes prior to intubation or 1 to 3 mcg/kg intravenously 
immediate prior to intubation attenuates hemodynamic responses. 
Mechanism of action of alpha 2 agonist is decreasing central sympathetic 
out flow, increasing the parasympathetic tone and by decreasing 
circulating nor-adrenaline concentration.
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4.  Intravenous vasodilators
Hydralazine
Sodium nitroprusside
Nitroglycerin
5. Narcotics 
Fentanyl    Morphine
Alfentanyl    Pethidine
Sufentanyl    Nalbhuphine
     Fentanyl is the most commonly used narcotic agent. It is a potent 
analgesic, has a short duration of action, does not increase intracranial 
tension and has minimal circulatory changes.
6. Adrenergic blocker
     Long acting:  metoprolol, phentolamine, propranolol, labetalol, 
Short acting: esmolol
Of these, esmolol is the most commonly used agent because of its
ultra short action. 
15
It reduces heart rate, systolic blood pressure, ejection fraction and 
cardiac index but it maintains coronary perfusion pressure.
7.  Calcium channel blockers
Nifedipine, nicardipine , verapamil, diltiazem Of these agents, 
nicardipine has got superior action. 
8. Sedative and anxiolytics: 
Midazolam and magnesium sulphate.
16
PHARMOCOLOGY OF THE STUDY DRUG
Dexmedetomidine
It is a highly selective α2 – adrenergic agonist that produces 
sedation, hypnosis and analgesia.
History
The initiation for the use of α2 agonist in anesthesia resulted from 
observations made in patients during anesthesia who were receiving 
clonidine therapy. Dexmedetomidine was introduced in clinical practice in 
the United States in 1999. It was approved by FDA only as a short term 
(<24 hours) sedative for mechanically ventilated adult ICU patients.
Dexmedetomidine is now being used off-label outside of the ICU in 
various settings
Pharmacological profile
It is a highly selective α2 –adrenergic agonist. It shows a high ratio 
of specificity for the α2 receptor (α2/ α1 1600:1) compared with clonidine 
(α2/ α1 200:1), making it a complete α2 agonist. Dexmedetomidine 
belongs to the imidazole subclass of α2 receptor agonists, similar to 
clonidine. It is freely soluble in water.
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Metabolism and pharmacokinetics
Dexmeditomidine has rapid redistribution half life -6min 
.Dexmedetomoidine is 94 % protein bound, and its concentration ratio 
between whole blood and plasma is 0.66. Metabolism: biotransformation 
by conjugation methylation (21%), or hydroxylation followed by 
conjugation in liver. The inactive metabolites are excreted in urine and 
feces. The elimination half-life of dexmedetomidine is 2-3 hours, with a 
context- sensitive half time ranging from 4 minutes after a 10 minute
infusion to 250 minutes after an 8 hour infusion. No accumulation after 
infusions of 12-24 hrs duration.
Pharmacokinetics is similar in young adults and elderly.
Mechanism of actions
A selective α2-adrenoceptor agonist. Its action is unique and 
different. Three subtype of α2 adrenoreceptors have been described in 
humans: α2A, α2B and α2C
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Structural formula
α2A adrenoreceptors are primarily distributed in the periphery, whereas 
α2B and  α2C are in the brain and spinal cord.
 Presynaptic activation  of α2- adrenoreceptors inhibit the release of 
nor -epinephrine.
 Postsynaptic activation of α2- adrenoreceptors in the central nervous
system inhibits sympathetic activity and can decrease blood pressure 
and heart rate, so sedation and anxiolysis can result from this 
activity.
 Analgesia is provided through binding of dexmedetomidine to α2 
adrenoreceptors in the spinal cord.
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The overall response to α2adrenoreceptor agonist is related to the 
stimulation of α2adrenoreceptor located in the central nervous system and 
spinal cord. The α2 agonists produce their sedative – hypnotic effect by an 
action on α2 receptor in the locus caeruleus and an analgesic action at α2 
receptors within the locus caeruleus and within the spinal cord.
Action
Effect on central nervous system 
Sedation 
The α2 agonists act through the endogenous sleep- promoting 
pathways to exert their sedative effect.
It produces a unique sedative quality – someone be clinically sedated 
yet arousable
 Patient sedated , remaining so when unstimulated . but when 
stimulated they are arousable, alert, and able to respond without 
becoming uncomfortable 
 It’s also observed that they would quickly return to their sleep –like 
state.
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 This characteristic allows for “daily wake up” tests to be done in a 
safe fashion.
 Despite sound levels of sedation with dexmedetomidine, there is 
limited respiratory depression, providing wide safety margins.
Analgesia 
     The analgesic effects of dexmedetomidine are complex. α2 agonists do 
have an analgesic effect when injected via the intrathecal or epidural route. 
The primary site of analgesic action is thought to be the spinal cord.
Systemic use of dexmedetomidine shows narcotic sparing. In the 
postoperative     ICU setting, narcotic requirements were reduced by 50% 
when patients were receiving dexmedetomidine.
     In human pain studies, the results of systemically administered 
dexmedetomidine are inconsistent. Modest reductions in pain was
observed.
In the clinical setting, when pain is likely to occur, if dexmedetomidine is 
to be used, the addition of a narcotic seems warranted.
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Other central nervous system effects 
Dexmedetomidine in animal models of incomplete cerebral ischemia 
and reperfusion reduces cerebral necrosis and improves neurologic 
outcome by reducing the intracerebral catecholamine outflow and the 
reduction of the excitatory neurotransmitter glutamate during injury.
Dexmedetomidine also is able to reduce muscle rigidity after high-
dose opioid administration.
Effects on the respiratory system 
Dexmedetomidine at concentrations producing significant sedation 
reduces minute ventilation, but retains the hypercapnic ventilatory 
response. The changes in ventilation appeared similar to those observed 
during natural sleep. Dexmedetomidine has been implicated in blocking 
histamine–induced bronchoconstriction in dogs.
Effects on cardiovascular system
The basic effects of α2 agonist on the cardiovascular system are 
decreased heart rate, decreased systemic vascular resistance and indirectly 
decreased myocardial contractility, cardiac output, and systemic blood 
pressure. 
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The hemodynamic effects of a bolus of dexmedetomidine in humans
have show a biphasic response- an initial increase in blood pressure (22%)
and decrease in heart rate (27%) from baseline that occurred at 5 minutes
after injection (probably due to the vasoconstrictive effects of 
dexmedetomidine when stimulating peripheral α2 receptors) followed by 
heart rate return to base line by 15 minutes, and blood pressure decrease 
15% below base line by 1 hour.
     The incidence of hypotension and bradycardia may be related to the 
administration of a loading dose. Omitting the loading dose or not giving 
more than 0.4µg/kg reduces the incidence of hypotension. Giving the 
loading dose over 20 minutes also minimizes the transient hypertension.
Dosage and administration
 Dexmedetomidine is supplied in a 2-ml ampoule, 100 mcg/ml.
 Dexmedetomidine must be diluted in 0.9% sodium chloride to 
achieve the required concentrations prior to administration. To 
prepare the infusion, withdraw 2ml of dexmedetomidine and add to 
48 ml of 0.9% sodium chloride injection to total of 50 ml.
 The target concentration is 4mcg/ml. so 2ml of dexmedetomidine 
needs to be diluted to 50 ml in 0.9% sodium chloride.
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 Loading  dose – 0.5µg-1µg/kg (6-12ml)over 10min [36-72ml/hr]
 Maintenance -0.3µg-0.7µg /kg/hr(4-9ml/hr)
 Titration ±0.1µg/kg/hr- 1.25 ml/hr
Uses 
Dexmedetomidine has been approved as a short term sedative for 
adult intubated patients in ICU. Given its well – documented beneficial 
effects of anxiolysis, sedation, analgesia, and sympatholysis with minimal
respiratory depression , it also has been used in various other clinical 
scenarios .
1. Intensive care unit 
Dexmedetomidine has following advantages for sedation in 
mechanically ventilated postoperative patients.
 Decreased requirement for opioids (>50%) when Dexmedetomidine 
is used for sedation compared with propofol or benzodiazepines. 
 The PaO2/ FIO2 ratio was significantly higher in the 
Dexmedetomidine  group 
 Providing adequate sedation with minimal respiratory depression –
can be used when weaning patients from the ventilator.
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α 2 adrenoreceptor agonists have been used in the treatment of alcohol and 
drug withdrawal of narcotics, benzodiazepines, alcohol, and recreational 
drugs.
2. Anesthesia 
a) Dexmedetomidine at IV doses of 0.33 to 0.67 µg/kg given 15 
minutes before surgery attenuates the hemodynamic response to 
endotracheal intubation. 
b) As a premedicant IM injection (2.5µg/kg)
c) Dexmedetomidine is used as a premedication 10 minutes before 
general surgery for cataract removal. Intra ocular pressure is 
decreased (33%) catecholamine secretion is reduced, perioperative 
analgesic requirements are less and recovery is very rapid 
d) Dexmedetomidine is used for securing the airway with a fiberoptic
intubation 
e) Dexmedetomidine has been used for sedation for monitored 
anesthesia care in gynecological, urological, burns patients, trauma 
patients, and pediatric patients and in obese, OSA patients.
f) Sedation during regional anesthesia.
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g) Dexmedetomidine is also useful as anesthetic adjuvant in Bariatric 
surgery, sleep-apnea patients, craniotomy aneurysm, AVM   
[hypothermia], cervical spine surgery, off pump CABG, vascular 
surgery, thoracic surgery, injury, burns, trauma, alcohol withdrawal.
Contraindications
 Infusion over 24 hours 
 In obstetric procedures, caesarean section deliveries, the safety has
not been studied. 
 Patients with pre-existent severe bradycardia and related
bradydysrhythmias (e.g., advanced heart block)
 Patients with impaired ventricular function ( ejection fraction <30%)
 Patients who are hypovolemic or hypotensive. 
 Patients with raised intracranial tension 
Antidote
All effects of Dexmedetomidine could be antagonized easily by 
administering the alpha 2 – adrenoceptor antagonist atipamezole (A-17)   
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REVIEW OF LITERATURE
1.   Tim G Costello  et al had done a study comparing 
hemodynamic responses to intubation and pin head holder application in 
two groups of neuro surgical patients given oral clonidine (3mg/kg) or oral 
Temazepam (10-20mg) , 90 min before induction of anesthesia.
Mean arterial blood pressure (MAP) and heart rate were recorded 
before the induction of anesthesia and before and after intubation and 
application of the pin head holder. Interventions required to maintain 
hemodynamic stability were compared between groups. Pre induction 
sedation stores and MAP values were similar between groups. MAP was 
significantly lower (p=0.031) in the clonidine group after pin head holder 
application. The study was concluded by observing that clonidine was 
effective in reducing the MAP increase with pin head holder application in 
neurosurgical patients. 
2. Menda F et al had conducted a study in which 
dexmedetomidine was compared with placebo or attenuate hemodynamic 
response to endotracheal intubation in patients undergoing fast track 
CABG.
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50 patients who were receiving β- blocker treatment were given 
dexmedetomidine (1mcg/kg) or placebo before induction of anesthesia. 
Heart rate (HR) and blood pressure (BP) were monitored at baseline, after 
placebo on dexmedetomidine infusion, after induction of anesthesia and at
one, three, and five minutes after endotracheal intubation.
In the dexmedetomidine group systolic (SAP), diastolic (DAP) and 
mean arterial pressure (MAP) were lower at all times in comparison to 
baseline values. In the placebo group SAP, DAP and MAP decreased after 
the induction of general anesthesia and five minutes after the intubation 
compared to baseline values. This decrease was not significantly different 
between the groups.
After the induction the drop in HR was higher in DEX group 
compared to PLA group. One minute after intubation, HR significantly 
increased in PLA group while, it decreased in the DEX group. The study 
was concluded by observing that dexmedetomidine can safely be used to 
attenuate the hemodynamic response to endotracheal intubation in patients
undergoing myocardial revascularization receiving β- blockers.
3. Uyar, Yagmurdur et al had done a study in which 
dexmedetomidine was compared with a placebo to attenuate the 
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hemodynamic and neuro endocrinal responses  to skull pin head holder 
application during craniotomy patients. In this study, 40 patients 
undergoing craniotomy with attachment of a pin holder were randomly 
assigned to one of two equal groups. The placebo group received saline, 
where as the treatment group (DEX group) received a single bolus of 
dexmedetomidine (1mcg/kg)., intravenously over 10 minutes before 
induction of anesthesia. Arterial blood pressure, heart rate and sequential 
concentrations of circulating cortisol, prolactin and blood glucose were 
measured. Relative to baseline and the other group, arterial blood pressure 
and heart rate decreased significantly after the administration of
dexmedetomidine through skull pinning (P<0.05).
In both the groups plasma cortisol, prolactin and blood glucose 
increased significantly relative to baseline and after skull pin insertion. 
However the values were significantly increased in the placebo group 
compared with the DEX group. The results suggested that a single bolus 
dose of dexmedetomidine before induction of anesthesia attenuated the 
hemodynamic and neuroendocrinal responses to skull pin insertion in 
patients undergoing craniotomy.
4.    Jellish W,et al conducted a study in which effects of clonidine 
premedication and scalp infiltration of lidocaine on hemodynamic 
responses to laryngoscopy and skull pin head holder insertion were 
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compared during skull base procedures . 34 patients undergoing skull base 
procedures were randomized to four groups. Group 1 received oral
clonidine 5mcg/kg before surgery with 10-15 ml of 1% Lidocaine 
infiltrated at pin insertion sites. Group 2 received clonidine with saline 
infiltration. Group 3 received a placebo preoperatively and had lidocaine 
infiltrated at pin sites. Group 4 received a placebo and saline infiltration at 
pin insertion sites.
They concluded that clonidine attenuated HR increases after 
laryngoscopy, but not after H-H placement. Lidocaine injected at the pin 
sites reduced HR but MAP increased after H-H insertion. The 
combination of oral clonidine and scalp lidocaine blunted hemodynamic 
responses to both intubation and H-H placement  
5.  Scheinin et al conducted a study where IV dexmedetomidine   
was compared with a placebo to attenuate the sympathoadrenal responses 
to tracheal intubation 
They studied in 24 ASA I patients, where either dexmedetomidine 
0.6mcg/kg or saline was given I. V, 10 minutes before induction of 
anesthesia. They found that the required dose of thiopentone was 
significantly smaller (p<0.001) in the dexmedetomidine groups than in the 
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control group and the drug attenuated the cardiovascular responses to 
laryngoscopy and tracheal intubation.
They concluded that dexmedetomidine attenuated the 
sympathoadrenal responses to tracheal intubation and reduces the need for 
thiopentone and pre operative fentanyl .
The stress response to laryngoscopy and endotracheal intubation 
activates the sympathetic nervous system, which may increase the 
myocardial oxygen   demand by increasing HR and arterial blood pressure. 
Of the various methods, high dose opioids may completely inhibit 
the stress response . These high doses of opioids are impractical.
6. Mollick MT, et al in a study used low dose of lignocaine or 
low dose of opioids and observed the cardiovascular response after 
laryngoscopy and endotracheal intubation. They used 100 patients of both 
sexes. The cardiovascular parameters observed were HR,(SBP,) systolic 
blood pressure , diastolic blood pressure (DBP), and rate pressure 
product(RPP). Group 1 received lignocaine(1mg/kg) 2 minutes before 
induction of anesthesia.  
Group II received inj. Pethidine 1mg/kg and inj. Lignocaine 1mg/kg 
intra venously . They concluded the study by observing that intravenous 
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lignocaine with pethidine did attenuate the sympathetic responses to 
laryngoscopy and endo tracheal intubation. 
7.   Dobblar DD, et al compared four techniques for preventing or 
blocking the hypertensive responses to the insertion of Mayfield headrest 
skull pin. Intravenous alfentanil, IV esmolol, IV thiopental sodium and 
local anesthesia using plain lidocaine.
Of the 40 patients undergoing intracranial surgery requiring the use 
of May field headrest skull pin, 20 min after anesthetic induction and 2-3 
minutes prior to insertion of head rest skull pin, one of these three drugs 
was administered IV. (Alfentanil 10 mcg/kg , esmolol 1mg/kg or 
thiopental 1.5mg/kg). The fourth drug lignocaine was administered by 
injection into the scalp. 
Blood pressure, heart rate were recorded immediately prior to and 
after pin insertion with balanced general anesthesia. 
This study was concluded by observing that IV alfentanil and local 
injection of xylocaine in the scalp prevented the hemodynamic response to 
the insertion of skull pins. Neither esmolol nor thiopentone prevented the 
hypertensive response. They further concluded that the rapid onset and 
short half life of alfentanil , coupled with the absence of hemodynamic 
effects at the dose used is an alternative to the use of lidocaine injection.
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8. Kenya ,et al conducted a study in which the efficacy of 
dexmedetomidine in attenuating the sympathoadrenal responses to tracheal 
intubation and also analyzed reduction in intra –operative anesthesia 
requirement.
Sixty patients scheduled for elective surgery of more than 3 hours 
were randomly selected .Control group received isoflurane-opioid and 
study group received isoflurane opioid- dexmedetomidine anesthesia  
given over 10 min before induction of anesthesia and continued in a dose 
of 0.2-0.7 mcg/kg/hr until skin closure. All patients were induced with 
thiopentone fentanyl and vecuronium. Hemodynamic variables were 
continuously recorded. 
The study resulted in observing that in the dexmedetomidine group , 
the need for thiopentone and isoflurane was decreased by 30% and 32% 
respectively. The conclusion of the study was that perioperative infusion of 
dexmedetomidine is effective in attenuating sympathoadrenal responses to 
tracheal intubation. They also concluded that dexmedetomidine has 
significant anesthetic and opioid sparing effect.
9.     Tanskanen PE, et al conducted a randomized double blind 
study in which dexmedetomidine was used as an adjuvant in patients
undergoing intracranial tumor surgery. In that study, it was concluded that 
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there was an increased perioperative hemodynamic stability in patients
undergoing brain tumor surgery without postoperative respiratory 
depression. 
10. Bloor BC, et al conducted a study on the effects of 
intravenous dexmedetomidine in humans II Hemodynamic changes . 
Here, they examined the hemodynamic effects of four selected IV 
doses in consenting healthy male volunteers. In a randomized trial subjects 
received 0(n=9), 0.25(n=6), 0.5(n=6), 1.0(n=6) or 2.0(n=10) mcg/kg of 
dexmedetomidine by infusion.
ECG, heart rate (HR), arterial blood pressure (MABP), 
bioimpedence cardiac output (CO) and plasma catecholamine
concentration (CA) were monitored from 90 min before to 360 min after 
infusion. Plasma dexmedetomidine concentrations were measured.
The study was concluded thus: Even the lowest dose decrease CA 
(catecholamines) immediately to values close to 20PCG/ml for 5 hrs and 
2min IV infusion of dexmedetomidine produced a transient increase in 
MABP and a longer lasting decrease in MABP and catecholamines .
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MATERIALS AND METHODS
This study was conducted after obtaining approval from the institute 
ethical committee and patients’ consent. Surgeon was informed of the 
study
Study design
Prospective randomized control study
Patient selection 
Age group:  18 – 70 years
Forty consecutive ASA I and II patients aged between 18 years and 
70 years old, undergoing elective craniotomy for resection of 
supratentorial tumor or clipping of an unruptured cerebral aneurysm with 
the aid of skull pin head holder were randomized in to 2 groups. 
This study was done during the period from July 2011 to September 
2011 in the department   of anesthesia, GGH. Chennai 3
Exclusion criteria 
1. History of endocrinology disease
2. HTN
3. IHD
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4. 2° and 3°heart block
5. Pregnancy
6. Lactation
7. Symptoms and signs of raised ICP
8. Head injury 
9. Presence of pre scalp incision 
10. All tumor of hypophysis
11. Patients not willing to participate in the study.
Materials 
1. Perfussor compact – syringe infusion pump.
2. Inj. Dexmedetomidine 2 ml amp, normal saline
3. Disposable 50 ml syringe 
4. Extension tube 
5. Weighing machine 
6. Monitors- ECG ., NIBP , SPO2 , ETCO2
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METHODOLOGY
Forty patients with the above criteria were divided in to two equal 
groups. Group DEX receives bolus dose of inj. Dexmedetomidine 1mcg/kg 
over ten minutes before induction of anesthesia. 
Group NS receives equal amount of normal saline. 
Pre operative investigations report like HB, blood urea , serum 
creatinine , platelets , clotting time , bleeding time , were recorded .
On arrival to the operating room, monitors were connected and 
baseline vital parameters were noted . Two peripheral IV lines with 18 G 
IV cannula , one for IV infusion and other  for the studied drug were 
started . Preloading was done with 10ml/kg of balanced salt solutions.
Patients received either IV Dexmedetomidine or placebo over a 
period of 10 min. before induction.
Then anesthesia was induced with inj. Thiopental 5mg/kg , inj.
Fentanyl 2mcg/kg and inj. Vecuronium 0.1mg/kg and intubated with 
appropriate size endotracheal tube .
Anesthesia was maintained with 66% N2 O, 33% O2 + IPPV and 
vecuronium.
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The patients’ ventilation was controlled to maintain a target value of 
end tidal co2 between 33 and 38 mmHg .
One minute pin before pin insertion 1mcg/kg fentanyl and 1.5mg/kg 
lignocaine were given IV to all patients as a standard in our institute.  Then 
the skull pin, with all its connections were prepared for being attached, was 
placed within a few minutes. Throughout the operation, 1mcg/kg fentanyl 
was administered every 45 min until the last 30 min of surgery. 
Any incidence of hypotension or bradycardia was recorded. 
Hypotension is defined as decreased in MAP 30% or more from baseline 
treated with inj. Ephedrine or Atropine 0.6mg 
Hemodynamic measurement and blood sampling
The outcome variables of HR and MAP were recorded at the following 
time intervals. 
 Baseline value 20 min before IV administration of 
Dexmedetomidine or placebo. 
 T0 : 1 min before the pin insertion.
 T1, T5,T10, :  1,5and 10 min , respectively after pin insertion.
Blood samples were obtained 15 min before IV administrations of 
Dexmedetomidine or placebo (baseline) and at 30 min after the pin 
38
insertion for the determination of plasma glucose, cortisol and prolactin 
levels.
     Results were analyzed and tabulated.
Statistical analysis
Results for parametric data were reported as means± SD 
Demographic parameter data were analyzed by student‘t’ tests.
Non parametric data were analyzed using x2  test 
Hemodynamic data and hormone levels were analyzed by the 
independent‘t’ tests for differences between group and the paired ‘t’ test 
for differences within groups .
For post- hoc comparison, Bonferroni  test was applied . 
A value of <0.05 was considered as statistically significant  
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OBSERVATIONS & ANALYSIS
Table I: Demographic Profile –AGE 
Forty patient were taken in to the study group 20 belong to the group
NS and remaining 20 belong to DEX .
GROUP N Mean
Std. 
deviation
P
Age in 
yrs
NORMAL 
SALINE
DEXMED
20
20
41.55
46.10
11.601
11.369
> 0.05
Not 
significant
     The mean age and age distribution in both the groups were found to be 
similar.  P value was found to be not significant 
Table 2: Demographic Profile –Sex 
GROUP
TOTALNORMAL SALINE DEXMED
SEX MALE
COUNT %
WITHN IN GROUP
12
60.0%
15
75.0%
27
67.5%
FEMALE
COUNT %
WITHN IN GROUP
8
40.0%
5
25.0%
13
32.5%
TOTAL
COUNT %
WITHN IN GROUP
20
100.0%
20
100.0%
20
100.0%
            Of the 40 patients, 27 were males and 13 were females. The 
distributions were similar in both the group of patients.
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Table 3: Demographic profile -ASA PS status
   In group NS,6 patients were ASA I, 13 were ASA II , and 1 
patient was in ASA III.
In group DEX  7 patients were ASA I, 13 patient were ASA II
The data is statistically not significant ( p>0.05) and these both 
groups are comparable in terms of ASA PS status 
              
GROUP
TOTALNORMAL 
SALINE
DEXMED
ASA
I
COUNT %
WITHN IN 
GROUP
6
30.0%
7
35.0%
13
32.5%
II
COUNT %
WITHN IN 
GROUP
13
65.0%
13
65.0%
26
65.0%
III
COUNT %
WITHN IN 
GROUP
1
5.0%
0
0%
1
2.5%
TOTAL
COUNT %
WITHN IN 
GROUP
20
100.0%
20
100.0%
40
100.0%
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Table IV :  Heart rate changes (beats /min)
         
BASE LINE HEMODYNAMIC PARAMETERS:
There was no statistically significant difference in the base line 
hemodynamic parameters between the two groups.
The lowest level of heart rate for the DEX group was 68± 8.615 and 
was observed at T0. This was significantly lower than the baseline value. 
Pin attachment significantly increase heart rate at T1 , T5and T10
20 86.05 7.373
20 86.15 5.687
P=0.962 not
significant
20 68.00 8.615 <0.05 
20 80.45 5.586 significant
20 81.60 7.883 <0.05
20 99.80 5.578 significant
20 75.65 6.968 <0.05
20 88.70 3.988 significant
20 70.70 6.744 <0.05
20 86.20 3.820 significant
GROUP
DEX
NS 
DEX
NS
DEX
NS
DEX
NS
DEX
NS
HR - BASELINE
HR - T0
HR - T1
HR - T5
HR - T10
N Mean Std. Deviation   P
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Table V :  Mean arterial pressure changes (mmHg)
     The lowest level of MAP was observed in the DEX group. It was 
76.95± 5.276 at T0. This was significantly lower than the base line value. 
Pin attachment significantly increased the MAP level at T1, T5 and T10 (< 
0.05)  
20 97.50 5.267 P=0.849 not
20 97.80 4.584 significant
20 76.95 5.276 <0.05
20 93.40 5.276 significant
20 89.90 4.844 <0.05
20 119.20 5.053 significant
20 86.05 4.989 <0.05
20 112.55 5.558 significant
20 80.45 5.145 <0.05
20 97.45 4.883 significant
GROUP
DEX
NS
DEX
NS
DEX
NS
DEX
NS
DEX
NS
MAP - BASELINE
MAP - T0
MAP - T1
MAP - T5
MAP - T10
N Mean Std. Deviation
      P   
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Table VI:  HORMONAL CHANGES – BLOOD SUGAR 
  
GROUP N MEAN
Std 
Deviation
P
RBS-
BASELINE
NORMAL 
SALINE
DEXMED
20
20
75.15
71.30
14.005
9.576
=0.317
Not 
significant
RBS-AFTER
NORMAL 
SALINE
DEXMED
20
20
127.90
05.65
26.987
19.535
< 0.05
significant
The base line value was not statistically significant. Sample taken 30 
min after pins were statistically significant (P<0.05)
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Table VII: HORMONAL CHANGES - PROLACTIN
GROUP N MEAN
Std 
Deviation
P
PROLACTIN 
–
BASELINE
NORMAL 
SALINE
DEXMED
20
20
13.6880
10.3490
9.56236
6.49961
=0.204
Not 
significant
PROLACTIN
-AFTER
NORMAL 
SALINE
DEXMED
20
20
60.3050
22.4325
47.27146
20.92367
=0.002
significant
  
    Base line value showed P=0.204 which is not significant while 
values taken after pin insertion shows P= 0.002 which is statistically 
significant 
Table VIII:  HORMONAL CHANGES - CORTISOL
    
GROUP N MEAN
Std 
Deviation
P
CORTISOL 
–
BASELINE
NORMAL 
SALINE
DEXMED
20
20
8.7785
9.9530
4.55955
4.46692
=0.416
Not 
significant
CORTISOL 
–
AFTER
NORMAL 
SALINE
DEXMED
20
20
20.2505
16.0930
4.90432
7.72431
=0.049
significant
Base line value showed P=0.416 which is not significant while 
values taken after pin insertion shows a P= 0.049 which is statistically 
significant 
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DISCUSSION
This study demonstrated that preoperative administration of single 
bolus of dexmedetomidine attenuates increase in HR and MAP in neuro 
surgical patients during skull pin insertion. The concomitant modulation of 
increases in plasma cortisol , prolactin, and glucose concentrations 
suggests that this hemodynamic effect is mediated by the sympatholytic
properties  of   dexmedetomidine.
Control of hemodynamic parameters during neurosurgical 
procedures is of great concern to the neuro-anesthesiologist whose goals 
include ensuring optimal cerebral perfusion pressure.
Even very deep general anesthesia via inhalation or narcotic, cannot 
reliably ablate the response to various surgical stimuli and may 
compromise arterial blood pressure and hence cerebral blood flow in the 
susceptible patient. 
Skull pin insertion is an intense nociceptive stimulus that 
dramatically increases HR and MAP.
Gonzalez et al15 studied the hemodynamic response to application of 
neurological skull pin head holder.
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Low et al16 in their studies of anesthesia in relation to hypertension
concluded that the skull pin stimulus is similar to the response to 
laryngoscopy and intubation, which is mediated by stress hormone release 
and is exaggerated in patients with chronic hypertension.
Ozkose z,23 et al believed that it is likely mediated by stress 
hormones via the same sympathoadrenal reflex .
The insertion of skull pins, though producing similar hemodynamic 
responses in anesthetized patients, differs from laryngoscopy and 
intubation in that it is a more reproducible stimulus each time is applied, is 
less dependent on the skills and timing of the operator, and anatomic 
considerations. This was thought out by Jellish17 WS and colleagues.
  This “uniform” stimulus should be blunted in neurosurgical patients
to avoid unwanted increases in blood pressure, HR and ICP
Costello18 TG and colleagues had used clonidine to decrease 
hemodynamic responses to pin head holder application during craniotomy 
surgeries.
Also, Talke19 P and colleagues, Bekker A et al, Souter MJ used 
dexmedetomidine in prevention of hemodynamic and endocrine responses 
to skull pin placement for craniotomies.
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Although lignocaine can be given as local anaesthesia at the sites of 
the pin insertion , in our institute, both fentanyl and lignocaine were give 
IV  at the same dose and time to all patients. Thus the differences in 
hemodynamic and neuroendocranial responses between groups could be 
attributed to dexmedetomidine. 
The hemodynamic effects of dexmedetomidine are predictable from 
the pharmacology of alpha adrenoreceptor agonists11,24,25.
The hypotensive and bradycardia effects of dexmedetomidine are 
presumably mediated by the sympatholytic effect of dexmedetomidine. 
Which is confirmed in this study by significant reduction of cortisol, 
prolactin and glucose levels in the dexmedetomidine group compared with 
NS groups.
The most conspicuous neuroendocrine markers of stress are the 
rapid increase in corticotrophin release hormone, corticotrophin , 
glucocorticoid (cortisol) levels , the activation of hypothalamic, nor 
adrenergic output , which enhances glucose production in the liver , and 
the increased release of the hyper glycaemic hormones adrenaline and 
glucagon . There is also a fall in insulin levels which is mediated by 
adrenaline26.
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The prolactin release from the pituitary gland is a very sensitive 
marker of both physical and psychological stress in mammals. The 
prolactin surge results from a general increase in the adrenergic activity in 
the hypothalamus. The stress induced prolactin release is a rapid, strong 
and transient response that can be evoked by a large number of medical 
and surgical procedures26,28
Therefore in our study investigating the effect of dexmedetomidine
in endocrine response to skull pin insertion for craniotomies, we examined 
both the plasma cortisol and prolactin levels in relation to glucose 
concentrations. 
     Dexmedetomidine was not found to affect the process of 
steriodogenesis, as proven by the work of Venn29 et al, who demonstrated 
that dexmedetomidine did not affect the response to adrenocorticotrophic 
hormone stimulation test. However patients receiving dexmedetomidine in 
our study had significantly lower intraoperative cortisol levels as compared 
with those who didn’t receive the drug before surgery30. 
   Alpha-2 adrenoceptor agonists can cause hyperglycemia in 
humans31-34. The mechanism is thought to involve postsynaptic α-2 
adrenoceptor stimulation of pancreatic β-cells, which inhibits insulin 
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release. We found that dexmedetomidine did inhibit the hyperglycemic 
response to skull pinning significantly more than placebo, and this may 
reflect attenuation of sympathoadrenal response. Because of its 
sympatholytic action, dexmedetomidine suppresses parts of the endocrine 
surgical stress response with potential impact on perioperative glucose 
homeostasis35.Increased plasma concentrations of stress hormones 
stimulate glucose production, and by counter acting the action of insulin, 
decreased glucose utilization, resulting in hyperglycemia8. In our study 30 
min after skull pin insertion plasma cortisol and prolactin level 
significantly increased in the NS group than the DEX group. 
In this study comparison of intravenous dexmedetomidine 
(1mcg/kg) and placebo was done in attenuating circulatory and 
neuroendocrine responses to skull pin application. 
In patients undergoing general or gynecological surgery, numerous
studies have shown that dexmedetomidine blunts cardiovascular response
to intubation. In addition to this beneficial property of α 2 agonist, they 
have also been reported to increase the risk of hypotension and 
bradycardia.  In our study there was no instance of bradycardia, as the 
bolus drug was given slowly over a period of 10 min. 
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There could be few limitation of our study. First, we could not 
measure the plasma catecholamine levels to substantiate our hypothesis 
owing to the lack of laboratory facilities. The second is that it was 
performed in patients with good cardiac function. Patients with cardiac 
disease may be at high risk for developing significant bradycardia and 
hypotension.
We conclude that preoperative dexmedetomidine administration can 
be a useful adjuvant in neurosurgical procedures.
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SUMMARY
This study was done to compare the efficacy of a bolus injection of 
dexmedetomidine with a placebo on attenuating the sympathoadrenal 
response accompanying May Field Skull Pin application in 40 patients 
divided into two groups 
Group DEX: Dexmedetomidine 1mcg/kg
Group NS: Normal saline as a placebo 
40 ASA I and II patients aged 18 to 60 yrs undergoing elective 
craniotomy surgeries under general anesthesia were chosen for the study. 
After obtaining ethical committee approval the study population was 
chosen. Informed written consent was obtained from the patients. Heart 
rate, mean arterial blood pressure, blood sugar values, serum prolactin and 
cortisol levels were recorded as baseline values.
All patients were monitored with ECG, pulse oximetry, ETCO2 
continuously and NIBP intermittently. Patients received study drug just 
prior to induction of anesthesia according to the group. HR, MAP, was
monitored 1 min before insertion of the skull pin and 1, 5and10 min after 
skull pin insertion. Blood sampling was done for blood sugar, serum 
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cortisol and serum prolactin levels 20 min before induction of anesthesia 
and 30 min after skull pin insertion.
    Dexmedetomidine is a highly selective and potent α 2 
adrenoreceptor agonist. It is a pure α 2 agonist receptor agonist (α1:α2
ratio – 1:1600) than clonidine which has only less selective agonist activity 
(α1:α2 ratio 1:200)
In this study which was carried out in the institute of 
aneasthesiology and critical care at Madras Medical College Hospital, we 
evaluated the efficacy of dexmedetomidine in attenuating hemodynamic
and neuro endocrinal stress response ( increase in heart rate and increase in 
mean arterial pressure ) , (increase in blood sugar, serum cortisol, serum 
prolactin) to May Field Skull Pin insertion .
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CONCLUSION
     I conclude that dexmedetomidine 1mcg / kg given slowly over 10 min 
intravenously just prior to induction of anesthesia attenuates the 
cardiovascular and neuro-endocrinal responses to skull pin head holder 
application.
May Field Head Rest

NS Age in 
Years
Sex HR - T1 HR- T5 HR - T10 MAP -BL MAP - T0 MAP - T1 MAP - T5 MAP - T10 RBS 
-BL
RBS 
-AFTER
PROLACTIN 
-baseline
PROLACTIN 
-AFTER
CORTISO
L -
CORTISOL 
-AFTER
SAKTHIVEL 19 Male 75 71 68 98 78 89 86 81 67 90 16.97 26.02 13.73 19.42
THI RAVIYAM 53 Femal
e
70 66 63 96 80 93 90 86 85 177 30.69 128.20 5.66 16.74
THILAGAVATHY 32 Femal
e
76 70 66 103 80 92 93 87 56 77 11.12 92.40 3.47 13.46
SHANMUGAM 50 Male 83 77 72 100 81 93 90 80 96 127 40.50 41.76 5.42 7.75
RAMESH 53 Male 90 84 80 88 70 87 84 80 73 99 13.89 23.86 11.46 22.40
KANNAGI 30 Femal
e
86 80 76 90 71 80 77 73 68 98 31.62 147.90 5.40 17.89
MUTHU 50 Male 98 92 86 93 70 84 80 74 77 123 10.53 24.62 7.56 23.40
THAYALNAYGI 45 Femal
e
86 80 74 100 81 94 90 83 62 103 7.26 160.60 16.98 23.62
GOVINDAMMAL 48 Femal
e
73 68 66 97 79 90 87 80 122 135 15.62 58.15 17.49 26.57
SIVA ANANDAN 35 Male 82 77 70 96 78 88 85 80 66 128 8.66 25.54 15.40 27.80
VENKATESHAN 40 Male 96 86 81 109 90 104 95 91 74 120 5.46 10.53 7.64 22.40
PREM KUMAR 36 Male 80 72 71 90 71 86 80 74 66 140 7.53 103.86 3.56 15.46
SARADHA 40 Femal
e
86 80 72 92 70 90 92 87 68 132 5.78 23.68 15.76 22.85
RANI 37 Femal
e
84 77 73 94 70 86 80 74 78 143 10.56 121.24 7.36 19.47
MANIKANDAN 65 Male 76 70 66 101 76 88 84 80 80 188 10.51 39.36 5.74 24.56
KARRUPAIYAN 53 Male 90 82 76 103 80 92 88 84 77 123 8.54 40.50 6.54 22.56
PUSHPALATHA 26 Femal
e
72 68 60 102 81 94 90 84 68 136 5.89 23.66 6.86 17.88
RAMASAMY 29 Male 76 71 65 100 76 89 86 80 70 130 8.56 40.70 7.54 22.36
GOVINDA RAJ 36 Male 75 70 66 97 77 88 80 73 76 156 13.26 54.86 6.12 23.80
MAYAVAN 54 Male 78 72 63 101 80 91 84 78 74 133 10.81 18.66 5.88 14.62
DEXM ED Age in 
Years
Sex ASA HR - HR - T0 HR - T1 HR- T5 HR - T10 MAP - BL MAP - T0 MAP - T1 MAP - T5 MAP -
T10
RBS - BL RBS - PROLACTI
N -
PROLACTI
N - AFTER
CORTISOL 
-BaseLine
CORTISOL 
-AFTER
VELU 55 Male II 84 77 101 97 93 102 100 126 120 103 68 88 10.16 16.67 3.22 8.88
DHANABAL 52 Male II 78 80 96 90 89 96 90 116 113 95 87 112 8.65 24.67 7.03 12.12
KRISHNAVENI 43 Female I 86 83 98 92 88 98 92 114 110 95 58 72 8.54 18.86 16.62 28.54
POUNAMMAL 50 Female II 80 79 99 90 87 104 100 118 110 106 70 111 29.61 108.24 14.41 28.76
VELUSAMY 55 Male I 85 77 90 86 84 100 96 120 109 100 72 101 18.62 19.40 3.77 6.99
BALASUBRAMANI 28 Male II 92 89 111 90 92 104 100 126 120 104 65 82 5.32 12.30 18.55 21.89
CHELLAMMAL 48 Female II 97 90 109 91 89 90 82 118 113 88 76 90 7.28 11.62 12.41 18.59
VENUGOPAL 35 Male I 90 86 100 88 84 96 90 115 108 94 74 92 3.46 28.86 15.22 13.67
PAPPAAMMAL 56 Female II 82 77 99 89 83 98 98 125 118 99 68 107 18.20 21.42 7.22 19.44
MADAVAN 39 Male I 87 80 97 90 87 101 96 123 115 98 92 114 12.36 18.30 4.88 7.32
PACHAIAPPAN 42 Male II 91 78 98 91 87 97 90 110 105 94 72 89 3.88 18.28 6.42 18.31
UDAYAKUMAR 35 Male I 83 76 100 92 90 96 90 118 103 93 56 123 11.12 20.62 5.74 8.62
GOVINDARAJ 56 Male II 90 82 104 88 89 104 102 120 118 105 76 140 7.84 18.62 12.72 26.72
SUHASHINI 28 Female I 79 73 90 80 82 89 88 117 112 92 58 84 4.82 10.50 11.42 13.56
VARADHARAJAN 33 Male II 85 84 98 86 84 94 90 115 109 94 68 92 5.72 8.72 11.22 18.72
PACHAMUTHU 68 Male II 86 79 99 90 88 90 92 119 111 96 74 126 7.54 15.34 8.76 12.84
MARIMUTHU 60 Male II 83 77 93 80 82 96 90 116 109 95 72 117 11.57 23.62 7.03 11.52
SARAVANAN 48 Male II 93 88 102 86 80 102 100 118 110 104 59 123 18.72 26.32 6.56 1.25
SIVAKOLUNDHU 56 Male II 77 68 104 86 79 99 90 132 126 96 77 107 5.44 10.77 12.24 18.62
ARUMUGAM 35 Male I 95 86 108 92 87 100 92 118 112 98 84 143 8.13 15.52 13.62 25.50
NS
Age 
in 
Years
Sex ASA HR -
HR -
T0
HR -
T1
HR- T5
HR -
T10
MAP -
BL
MAP -
T0
MAP -
T1
MAP -
T5
MAP -
T10
RBS -
BL
RBS -
PROLACTIN 
– Base
Line
PROLACTIN 
- AFTER
CORTISOL 
–Base
Line
CORTISOL 
-AFTER
SAKTHIVEL 19 Male II 89 62 75 71 68 98 78 89 86 81 67 90 16.97 26.02 13.73 19.42
THI RAVIYAM 53 Female III 73 58 70 66 63 96 80 93 90 86 85 177 30.69 128.20 5.66 16.74
THILAGAVATHY 32 Female II 83 63 76 70 66 103 80 92 93 87 56 77 11.12 92.40 3.47 13.46
SHANMUGAM 50 Male II 83 70 83 77 72 100 81 93 90 80 96 127 40.50 41.76 5.42 7.75
RAMESH 53 Male I 90 77 90 84 80 88 70 87 84 80 73 99 13.89 23.86 11.46 22.40
KANNAGI 30 Female I 87 73 86 80 76 90 71 80 77 73 68 98 31.62 147.90 5.40 17.89
MUTHU 50 Male I 102 86 98 92 86 93 70 84 80 74 77 123 10.53 24.62 7.56 23.40
THAYALNAYGI 45 Female II 85 72 86 80 74 100 81 94 90 83 62 103 7.26 160.60 16.98 23.62
GOVINDAMMAL 48 Female II 77 55 73 68 66 97 79 90 87 80 122 135 15.62 58.15 17.49 26.57
SIVA ANANDAN 35 Male II 91 67 82 77 70 96 78 88 85 80 66 128 8.66 25.54 15.40 27.80
VENKATESHAN 40 Male II 95 83 96 86 81 109 90 104 95 91 74 120 5.46 10.53 7.64 22.40
PREM KUMAR 36 Male II 80 67 80 72 71 90 71 86 80 74 66 140 7.53 103.86 3.56 15.46
SARADHA 40 Female II 86 73 86 80 72 92 70 90 92 87 68 132 5.78 23.68 15.76 22.85
RANI 37 Female I 83 70 84 77 73 94 70 86 80 74 78 143 10.56 121.24 7.36 19.47
MANIKANDAN 65 Male II 80 63 76 70 66 101 76 88 84 80 80 188 10.51 39.36 5.74 24.56
KARRUPAIYAN 53 Male II 91 78 90 82 76 103 80 92 88 84 77 123 8.54 40.50 6.54 22.56
PUSHPALATHA 26 Female I 77 56 72 68 60 102 81 94 90 84 68 136 5.89 23.66 6.86 17.88
RAMASAMY 29 Male I 99 63 76 71 65 100 76 89 86 80 70 130 8.56 40.70 7.54 22.36
GOVINDA RAJ 36 Male II 82 60 75 70 66 97 77 88 80 73 76 156 13.26 54.86 6.12 23.80
MAYAVAN 54 Male II 88 64 78 72 63 101 80 91 84 78 74 133 10.81 18.66 5.88 14.62
